^
    over2years
    Updated Guidelines from the American Urological Association Include Genomic Assays, such as the Oncotype DX GPS Test, for the First Time in Localized Prostate Cancer Patients (PRNewswire)
    "Exact Sciences Corp...announced the American Urological Association (AUA) updated their guidelines to include genomic assays, such as the Oncotype DX Genomic Prostate Score® (GPS™) test, when treating men with localized prostate cancer. The 2022 guidelines now state that clinicians may selectively use tissue-based genomic biomarkers when added risk-stratification may alter clinical decision-making....This is the first in-person AUA meeting where Exact Sciences will feature its full Oncotype® portfolio of urologic genomic assays, including the Oncotype DX® GPS test for localized prostate cancer; the Oncotype MAP™ Pan-Cancer Tissue test for solid tumors, including advanced prostate cancer; and the Oncotype DX AR-V7 Nucleus Detect® test for metastatic castration-resistant prostate cancer."
    Clinical guideline
    |
    Oncotype DX AR-V7 Nucleus Detect® test • Oncotype DX Genomic Prostate Score® Assay • Oncotype MAP™ Pan-Cancer Tissue Test
    over4years
    [VIRTUAL] AR enhancer and locus genomic alterations as cell-free DNA biomarkers of primary resistance to AR-directed treatment of metastatic prostate cancer. (ASCO 2020)
    "All patients received AR-directed therapy (eg. abiraterone, enzalutamide) and underwent standard-of-care clinical and laboratory follow-up. cfDNA-based AR/enhancer locus genomic alterations could potentially be used to predict primary resistance to AR-directed therapy with higher sensitivity than the clinically validated CTC AR-V7 assay, be used for serial timepoint monitoring and guiding personalized clinical decision-making. Research Funding: American Cancer Society and Siteman Cancer Center"
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • AR (Androgen receptor)
    |
    AR splice variant 7
    |
    Oncotype DX AR-V7 Nucleus Detect® test
    |
    Xtandi (enzalutamide) • abiraterone acetate